Phibro Animal Health Corporation reported strong second-quarter results, with a 26% increase in animal health sales and a substantial 41% rise in adjusted EBITDA, reflecting effective integration strategies and robust demand across key sectors.
- Animal health sales surged by 26%, led by a 34% growth in medicated feed additives.
- Consolidated sales rose 21% to $373.9 million, with EBITDA reflecting a 41% increase.
- Full-year sales and earnings guidance has been raised based on strong momentum and operational performance.
- Positive feedback from customers and strong leadership alignment highlight the company’s strategic execution and market position.
- Leadership transition slated for July is expected to reinforce momentum and operational excellence.
Community Discussion